Alejandro Álvaro

Learn More
BACKGROUND This study aimed to assess the costs and clinical benefits of the 13-valent pneumococcal conjugate vaccine (PCV13) administered annually to the 65-year-old cohort in Spain versus the alternative of not vaccinating patients and treating them only when infected. METHODS Cases of pneumococcal disease avoided were calculated through a dynamic model(More)
  • 1